Daihan Pharmaceutical Co.Ltd Working Capital to Net Assets Ratio
Daihan Pharmaceutical Co.Ltd working capital to net assets ratio. Daihan Pharmaceutical Co.Ltd (023910) has a Working Capital to Net Assets ratio of 37.9% as of September 2025. Working capital of ₩111.25 Billion (current assets of ₩154.89 Billion minus current liabilities of ₩43.64 Billion) is measured against net assets of ₩293.27 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Daihan Pharmaceutical Co.Ltd (2014–2024)
Working capital to net assets ratio of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. This chart shows how Daihan Pharmaceutical Co.Ltd's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the ratio stands at 37.9%, reflecting working capital of ₩111.25 Billion against net assets of ₩293.27 Billion KRW. Explore 023910 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Daihan Pharmaceutical Co.Ltd Working Capital to Net Assets Ratio by Year (2014–2024)
Daihan Pharmaceutical Co.Ltd working capital to net assets ratio by year from 2014 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Daihan Pharmaceutical Co.Ltd from 2014 to 2024, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Daihan Pharmaceutical Co.Ltd's balance sheet.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 34.3% | ₩94.72 Billion | ₩275.99 Billion | ₩137.37 Billion | ₩42.64 Billion | ▼ -13.5 pp |
| 2023 | 47.8% | ₩118.60 Billion | ₩247.97 Billion | ₩159.90 Billion | ₩41.30 Billion | ▼ -2.4 pp |
| 2022 | 50.2% | ₩113.20 Billion | ₩225.40 Billion | ₩155.89 Billion | ₩42.69 Billion | ▲ +0.2 pp |
| 2021 | 50.0% | ₩101.42 Billion | ₩202.81 Billion | ₩147.54 Billion | ₩46.12 Billion | ▲ +4.7 pp |
| 2020 | 45.3% | ₩82.46 Billion | ₩181.92 Billion | ₩121.68 Billion | ₩39.22 Billion | ▲ +4.3 pp |
| 2019 | 41.0% | ₩68.41 Billion | ₩166.78 Billion | ₩111.13 Billion | ₩42.72 Billion | ▲ +5.8 pp |
| 2018 | 35.2% | ₩49.47 Billion | ₩140.36 Billion | ₩104.97 Billion | ₩55.50 Billion | ▲ +0.7 pp |
| 2017 | 34.6% | ₩40.05 Billion | ₩115.88 Billion | ₩83.47 Billion | ₩43.42 Billion | ▲ +7.3 pp |
| 2016 | 27.3% | ₩25.36 Billion | ₩92.94 Billion | ₩73.66 Billion | ₩48.30 Billion | ▼ -11.8 pp |
| 2015 | 39.1% | ₩30.06 Billion | ₩76.84 Billion | ₩70.21 Billion | ₩40.15 Billion | ▲ +8.6 pp |
| 2014 | 30.6% | ₩19.59 Billion | ₩64.10 Billion | ₩62.77 Billion | ₩43.18 Billion | — |